Travere Therapeutics Files 8-K, Changes Principal Office

Ticker: TVTX · Form: 8-K · Filed: May 15, 2025 · CIK: 1438533

Travere Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyTravere Therapeutics, Inc. (TVTX)
Form Type8-K
Filed DateMay 15, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: administrative, corporate-info

Related Tickers: TTVX

TL;DR

Travere Therapeutics moved its HQ to San Diego, CA.

AI Summary

On May 15, 2025, Travere Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130. The company previously operated under the name Retrophin, Inc. and Desert Gateway, Inc.

Why It Matters

This filing updates the official contact and operational address for Travere Therapeutics, Inc., which is crucial for regulatory and investor communication.

Risk Assessment

Risk Level: low — The filing is a routine administrative update regarding the company's principal executive offices and does not indicate any material adverse events.

Key Players & Entities

  • Travere Therapeutics, Inc. (company) — Registrant
  • Retrophin, Inc. (company) — Former company name
  • Desert Gateway, Inc. (company) — Former company name
  • May 15, 2025 (date) — Date of report
  • 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 (location) — New principal executive offices

FAQ

What is the new principal executive office address for Travere Therapeutics, Inc.?

The new principal executive office address is 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130.

When was this 8-K report filed?

This 8-K report was filed on May 15, 2025.

What were some of Travere Therapeutics, Inc.'s former company names?

Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and Desert Gateway, Inc.

In which state is Travere Therapeutics, Inc. incorporated?

Travere Therapeutics, Inc. is incorporated in Delaware.

What is the Standard Industrial Classification code for Travere Therapeutics, Inc.?

The Standard Industrial Classification code for Travere Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 15, 2025 regarding Travere Therapeutics, Inc. (TVTX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.